tiprankstipranks
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market
RARE
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports
Want to see RARE full AI Analyst Report?

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

1,270 Followers
See the Price Targets and Ratings of:

RARE Analyst Ratings

Strong Buy
18Ratings
Strong Buy
16 Buy
2 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$55.82
▲(110.97% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $55.82 with a high forecast of $103.00 and a low forecast of $28.00. The average price target represents a 110.97% change from the last price of $26.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","41":"$41","62":"$62","83":"$83","104":"$104"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.82352941176471,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,41,62,83,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.91,30.916923076923077,36.923846153846156,42.93076923076923,48.93769230769231,54.94461538461539,60.95153846153846,66.95846153846153,72.96538461538462,78.9723076923077,84.97923076923077,90.98615384615384,96.99307692307693,{"y":103,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.91,27.28796380090498,29.665927601809955,32.043891402714934,34.42185520361991,36.79981900452489,39.17778280542987,41.55574660633484,43.93371040723982,46.3116742081448,48.68963800904977,51.06760180995475,53.44556561085973,{"y":55.82352941176471,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.91,25.147692307692306,25.385384615384616,25.623076923076923,25.860769230769233,26.09846153846154,26.336153846153845,26.573846153846155,26.81153846153846,27.049230769230768,27.286923076923078,27.524615384615384,27.762307692307694,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$103.00Average Price Target$55.82Lowest Price Target$28.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on RARE
Benjamin Burnett
Wells Fargo
Wells Fargo
$46→$50
Buy
88.96%
Upside
Assigned
08/28/26
Ultragenyx price target raised to $50 from $46 at Wells FargoUltragenyx price target raised to $50 from $46 at Wells Fargo
J.P. Morgan Analyst forecast on RARE
Anupam Rama
J.P. Morgan
J.P. Morgan
$75→$80
Buy
202.34%
Upside
Assigned
08/25/26
J.P. Morgan Issues a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Jefferies Analyst forecast on RARE
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$77
Buy
191.01%
Upside
Reiterated
08/21/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Jefferies
H.C. Wainwright Analyst forecast on RARE
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$50
Buy
88.96%
Upside
Reiterated
08/21/26
Ultragenyx: FDA-Backed Gene Therapy Momentum and Late-Stage Pipeline Support Reiterated Buy Rating and Unchanged $50 Price Target
Morgan Stanley Analyst forecast on RARE
Maxwell Skor
Morgan Stanley
Morgan Stanley
$67→$74
Buy
179.67%
Upside
Assigned
08/21/26
Analysts' Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)
Wedbush Analyst forecast on RARE
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$30
Hold
13.38%
Upside
Reiterated
08/20/26
Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
William Blair Analyst forecast on RARE
Sami Corwin
William Blair
William Blair
―
Buy
―
Initiated
08/20/26
Ultragenyx: Strengthening Gene Therapy Franchise and Upcoming Clinical Catalysts Support Buy Rating
Canaccord Genuity Analyst forecast on RARE
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$81→$83
Buy
213.68%
Upside
Reiterated
08/20/26
Ultragenyx price target raised to $83 from $81 at CanaccordUltragenyx price target raised to $83 from $81 at Canaccord
Citi Analyst forecast on RARE
Yigal Nochomovitz
Citi
Citi
$45→$58
Buy
119.20%
Upside
Reiterated
08/20/26
Ultragenyx price target raised to $58 from $45 at CitiUltragenyx price target raised to $58 from $45 at Citi
Goldman Sachs Analyst forecast on RARE
Salveen Richter
Goldman Sachs
Goldman Sachs
$27→$28
Hold
5.82%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Ascendis Pharma (NASDAQ: ASND) and Aurinia Pharmaceuticals (NASDAQ: AUPH)
Bank of America Securities Analyst forecast on RARE
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$46→$48
Buy
81.41%
Upside
Reiterated
08/20/26
Ultragenyx price target raised to $48 from $46 at BofAUltragenyx price target raised to $48 from $46 at BofA
TD Cowen Analyst forecast on RARE
Yaron Werber
TD Cowen
TD Cowen
$49
Buy
85.19%
Upside
Reiterated
08/19/26
Ultragenyx Pharmaceutical (RARE) Receives a Rating Update from a Top Analyst
Cantor Fitzgerald Analyst forecast on RARE
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$96→$103
Buy
289.27%
Upside
Reiterated
08/19/26
Cantor Fitzgerald Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Piper Sandler Analyst forecast on RARE
Allison Bratzel
Piper Sandler
Piper Sandler
$68
Buy
156.99%
Upside
Reiterated
08/17/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler
Evercore ISI Analyst forecast on RARE
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
24.72%
Upside
Reiterated
08/10/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on RARE
Benjamin Burnett
Wells Fargo
Wells Fargo
$46→$50
Buy
88.96%
Upside
Assigned
08/28/26
Ultragenyx price target raised to $50 from $46 at Wells FargoUltragenyx price target raised to $50 from $46 at Wells Fargo
J.P. Morgan Analyst forecast on RARE
Anupam Rama
J.P. Morgan
J.P. Morgan
$75→$80
Buy
202.34%
Upside
Assigned
08/25/26
J.P. Morgan Issues a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Jefferies Analyst forecast on RARE
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$77
Buy
191.01%
Upside
Reiterated
08/21/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Jefferies
H.C. Wainwright Analyst forecast on RARE
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$50
Buy
88.96%
Upside
Reiterated
08/21/26
Ultragenyx: FDA-Backed Gene Therapy Momentum and Late-Stage Pipeline Support Reiterated Buy Rating and Unchanged $50 Price Target
Morgan Stanley Analyst forecast on RARE
Maxwell Skor
Morgan Stanley
Morgan Stanley
$67→$74
Buy
179.67%
Upside
Assigned
08/21/26
Analysts' Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)
Wedbush Analyst forecast on RARE
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$30
Hold
13.38%
Upside
Reiterated
08/20/26
Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
William Blair Analyst forecast on RARE
Sami Corwin
William Blair
William Blair
―
Buy
―
Initiated
08/20/26
Ultragenyx: Strengthening Gene Therapy Franchise and Upcoming Clinical Catalysts Support Buy Rating
Canaccord Genuity Analyst forecast on RARE
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$81→$83
Buy
213.68%
Upside
Reiterated
08/20/26
Ultragenyx price target raised to $83 from $81 at CanaccordUltragenyx price target raised to $83 from $81 at Canaccord
Citi Analyst forecast on RARE
Yigal Nochomovitz
Citi
Citi
$45→$58
Buy
119.20%
Upside
Reiterated
08/20/26
Ultragenyx price target raised to $58 from $45 at CitiUltragenyx price target raised to $58 from $45 at Citi
Goldman Sachs Analyst forecast on RARE
Salveen Richter
Goldman Sachs
Goldman Sachs
$27→$28
Hold
5.82%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Ascendis Pharma (NASDAQ: ASND) and Aurinia Pharmaceuticals (NASDAQ: AUPH)
Bank of America Securities Analyst forecast on RARE
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$46→$48
Buy
81.41%
Upside
Reiterated
08/20/26
Ultragenyx price target raised to $48 from $46 at BofAUltragenyx price target raised to $48 from $46 at BofA
TD Cowen Analyst forecast on RARE
Yaron Werber
TD Cowen
TD Cowen
$49
Buy
85.19%
Upside
Reiterated
08/19/26
Ultragenyx Pharmaceutical (RARE) Receives a Rating Update from a Top Analyst
Cantor Fitzgerald Analyst forecast on RARE
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$96→$103
Buy
289.27%
Upside
Reiterated
08/19/26
Cantor Fitzgerald Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Piper Sandler Analyst forecast on RARE
Allison Bratzel
Piper Sandler
Piper Sandler
$68
Buy
156.99%
Upside
Reiterated
08/17/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler
Evercore ISI Analyst forecast on RARE
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
24.72%
Upside
Reiterated
08/10/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months
Whitney IjemCanaccord Genuity
Success Rate
11/17 ratings generated profit
65%
Average Return
+6.68%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +6.68% per trade.
1 Year
Yigal NochomovitzCiti
Success Rate
10/20 ratings generated profit
50%
Average Return
+0.36%
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.36% per trade.
2 Years
Yigal NochomovitzCiti
Success Rate
7/20 ratings generated profit
35%
Average Return
-12.05%
Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 35.00% of your transactions generating a profit, with an average return of -12.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
20
18
16
14
24
Buy
6
3
3
4
7
Hold
2
2
1
4
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
23
20
22
37
In the current month, RARE has received 31 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 55.82.
Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$0.86 with a range of -$1.30 to $0.75. The previous quarter’s EPS was -$0.90. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.
Next quarter’s earnings estimate for RARE is -$0.86 with a range of -$1.30 to $0.75. The previous quarter’s EPS was -$0.90. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $184.06M with a range of $168.00M to $203.12M. The previous quarter’s sales results were $214.00M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.
Next quarter’s sales forecast for RARE is $184.06M with a range of $168.00M to $203.12M. The previous quarter’s sales results were $214.00M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 55.82.
    What is RARE’s upside potential, based on the analysts’ average price target?
    Ultragenyx Pharmaceutical has 110.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RARE a Buy, Sell or Hold?
          Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Ultragenyx Pharmaceutical’s price target?
            The average price target for Ultragenyx Pharmaceutical is 55.82. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $103.00 ,the lowest forecast is $28.00. The average price target represents 110.97% Increase from the current price of $26.46.
              What do analysts say about Ultragenyx Pharmaceutical?
              Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of RARE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.